IRIS Accounts Production v25.2.0.378 15186168 director 1.11.24 31.3.25 31.3.25 false true false false false iso4217:GBPiso4217:USDiso4217:EURxbrli:sharesxbrli:pureutr:tonnesutr:kWh151861682024-10-31151861682025-03-31151861682024-11-012025-03-31151861682023-10-03151861682023-10-042024-10-31151861682024-10-3115186168ns15:EnglandWales2024-11-012025-03-3115186168ns14:PoundSterling2024-11-012025-03-3115186168ns10:Director12024-11-012025-03-3115186168ns10:PrivateLimitedCompanyLtd2024-11-012025-03-3115186168ns10:Micro-entities2024-11-012025-03-3115186168ns10:AuditExempt-NoAccountantsReport2024-11-012025-03-3115186168ns10:FullAccounts2024-11-012025-03-3115186168ns5:CurrentFinancialInstruments2025-03-3115186168ns5:CurrentFinancialInstruments2024-10-31
REGISTERED NUMBER: 15186168 (England and Wales)















Unaudited Financial Statements for the Period 1 November 2024 to 31 March 2025

for

Surrey Endocrinology Limited

Surrey Endocrinology Limited (by shares) (Registered number: 15186168)






Contents of the Financial Statements
for the Period 1 November 2024 to 31 March 2025




Page

Balance Sheet 1


Surrey Endocrinology Limited (by shares) (Registered number: 15186168)

Balance Sheet
31 March 2025

31.3.25 31.10.24
£    £   
FIXED ASSETS 600 960

CURRENT ASSETS 4,883 12,801

CREDITORS
Amounts falling due within one year (4,696 ) (5,257 )
NET CURRENT ASSETS 187 7,544
TOTAL ASSETS LESS CURRENT
LIABILITIES

787

8,504

CAPITAL AND RESERVES 787 8,504

NOTE TO THE FINANCIAL STATEMENTS

1. AVERAGE NUMBER OF EMPLOYEES

The average number of employees during the period was 2 (2024 - 2 ) .



The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the period ended 31 March 2025.

The members have not required the company to obtain an audit of its financial statements for the period ended 31 March 2025 in accordance with Section 476 of the Companies Act 2006.

The director acknowledges his responsibilities for:
(a)ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and
(b)preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

The financial statements have been prepared in accordance with the micro-entity provisions and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The financial statements were approved by the director and authorised for issue on 20 August 2025 and were signed by:





A Mohammadi - Director